Get the Stockscreener App
8.67
0.57%
-0.05
After Hours:
8.69
0.02
+0.23%
Lipocine Inc stock is traded at $8.67, with a volume of 18,209.
It is down -0.57% in the last 24 hours and down -3.99% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$8.72
Open:
$8.81
24h Volume:
18,209
Relative Volume:
0.15
Market Cap:
$48.14M
Revenue:
-
Net Income/Loss:
$-16.35M
P/E Ratio:
-2.8426
EPS:
-3.05
Net Cash Flow:
$-11.88M
1W Performance:
+12.31%
1M Performance:
-3.99%
6M Performance:
+191.92%
1Y Performance:
+145.61%
1-Day Range:
$8.5257
$9.15
1-Week Range:
$7.84
$9.3227
52-Week Range:
$2.52
$12.37
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
8.67 | 48.41M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15 - Finviz
S P Trends: Does Lipocine Inc offer margin of safetyMarket Activity Summary & Short-Term High Return Ideas - baoquankhu1.vn
Lipocine Announces Positive Interim Results for PPD Trial - MSN
Lipocine (LPCN) Price Target Increased by 58.18% to 11.09 - Nasdaq
Market Moves: Can Lipocine Inc ride the EV waveJuly 2025 News Drivers & Precise Swing Trade Alerts - baoquankhu1.vn
EV Market: Is Lipocine Inc a cyclical or defensive stockPortfolio Value Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress - Investing.com India
Lipocine completes enrollment in phase 3 trial for PPD treatment By Investing.com - Investing.com South Africa
Lipocine Completes Phase 3 Enrollment for Postpartum Depression Drug - TipRanks
Lipocine Inc Completes Enrollment in Phase 3 Trial for PPD Treatment - TradingView
Lipocine completes enrollment in phase 3 trial for PPD treatment - Investing.com
At-home postpartum depression drug from Lipocine tested in 90 women - Stock Titan
CEO Moves: Can Lipocine Inc ride the EV waveJuly 2025 Sector Moves & Fast Gaining Stock Reports - baoquankhu1.vn
Performance Recap: What is TREEs TAM Total Addressable MarketWeekly Market Outlook & Weekly High Return Opportunities - baoquankhu1.vn
LPCN 1154 for postpartum depression continues clinical process after safety review - Contemporary OB/GYN
Liver Cirrhosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Pfizer, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland - The Globe and Mail
Lipocine’s PPD drug trial continues after positive safety review By Investing.com - Investing.com India
Lipocine’s PPD drug trial continues after positive safety review - Investing.com
Lipocine Advances Phase 3 Postpartum Depression Drug Trial - TipRanks
Lipocine Inc Reports Progress in Phase 3 Trial for PPD - TradingView — Track All Markets
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PR Newswire
How Lipocine Inc. stock reacts to global recession fearsMarket Activity Report & High Accuracy Investment Entry Signals - ulpravda.ru
How Lipocine Inc. stock performs in stagflationTrade Risk Assessment & AI Forecasted Stock Moves - ulpravda.ru
How Lipocine Inc. stock benefits from strong dollarJuly 2025 Big Picture & Weekly Consistent Profit Watchlists - ulpravda.ru
Why Lipocine Inc. stock is considered a top pickJuly 2025 Big Picture & Fast Gain Stock Tips - Улправда
Why Lipocine Inc. stock could benefit from AI revolutionTrade Performance Summary & Free Fast Gain Swing Trade Alerts - Улправда
What is the fair value of Lipocine Inc. stock nowBear Alert & Reliable Entry Point Trade Alerts - ulpravda.ru
Lipocine price target lowered to $7 from $8 at H.C. Wainwright - MSN
Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL) - Defense World
Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154 - MSN
Aug PreEarnings: Can Lipocine Inc. stock outperform in 2025 bull marketQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - Улправда
Market Pulse: How Lipocine Inc. stock reacts to global recession fearsWeekly Trade Report & Long Hold Capital Preservation Tips - Улправда
Can Lipocine Inc. stock outperform in 2025 bull marketMarket Sentiment Report & Weekly High Return Stock Opportunities - Улправда
Does Lipocine Inc. stock trade at a discount to peersJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - Улправда
Return on equity % of Lipocine Inc. – BOATS:LPCN - TradingView — Track All Markets
Trend Review: Can Lipocine Inc. stock deliver consistent earnings growth2025 Valuation Update & Detailed Earnings Play Alerts - DonanımHaber
How Lipocine Inc. stock performs in high volatility marketsJuly 2025 Snapshot & Fast Gain Stock Trading Tips - DonanımHaber
Financial Review: Lipocine (NASDAQ:LPCN) vs. Astellas Pharma (OTCMKTS:ALPMY) - Defense World
Lipocine reaches 80% enrollment in postpartum depression drug trial By Investing.com - Investing.com Nigeria
Lipocine Advances Phase 3 Trial for PPD Treatment - TipRanks
Lipocine Inc Announces 80% Enrollment in PPD Phase 3 Study - TradingView — Track All Markets
Lipocine reaches 80% enrollment in postpartum depression drug trial - Investing.com India
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PR Newswire
Lipocine Inc. Announces Resignation of Jeffrey Fink as Director, Effective January 1, 2026 - marketscreener.com
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):